COX Nicox SA

Number of shares composing the share capital and total number of voting rights as of July 31. 2020

Number of shares composing the share capital and total number of voting rights as of July 31. 2020

Nicox SA

Société anonyme with a registered capital of € 33,491,370

Head Office:

DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis 

R.C.S. GRASSE 403.942.642

On August 3, 2020,

MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS

(Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF)

 As of July 31, 2020
Total number of shares composing the share capital33,491,370
Total number of voting rights33,491,370
Total number of voting rights, calculated based on the total number of shares, including the shares deprived of voting rights33,491,370

---------------



Phone: 00

Fax : 99

 

Attachment

EN
03/08/2020

Underlying

COXNicox SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nicox SA

 PRESS RELEASE
Free
COX NICOX SA

Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked an...

Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed Press Release Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed Company expects to fully repay existing financial debts in 2026NCX 470 NDA submissions in U.S. (H1 2026) and subsequently in China Milestones payable on U.S. NDA submission and on approvalGlaukos extends NCX 1728 research agreement Future strategic options under consideration including collaborations or business combinationsQ&A for shareholders available on the Nicox website: September 4, 2025 – r...

September 4, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox prévoit de rembourser intégralement ses dettes financières, NCX ...

Nicox prévoit de rembourser intégralement ses dettes financières, NCX 470 ayant été dé-risqué et licencié dans le monde entier Communiqué de presseNicox prévoit de rembourser intégralement ses dettes financières, NCX 470 ayant été dé-risqué et licencié dans le monde entier  La Société prévoit de rembourser intégralement les dettes financières existantes en 2026Dépôt des NDA1 pour NCX 470 aux Etats-Unis (au premier semestre 2026) puis ultérieurement en Chine Paiements d’étape prévus au dépôt de la NDA aux Etats-Unis et lors de son approbationExtension par Glaukos de l’accord de recherche po...

September 4, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox Announces Shareholder Q&A Webpage Available

Nicox Announces Shareholder Q&A Webpage Available Press Release Nicox Announces Shareholder Q&A Webpage AvailableAugust 26, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that a new webpage “Q&A” is available on the company’s website, , including information on the most frequently asked questions for shareholders in the form of a Q&A about Nicox and its business. The Q&A page can be reached here: Any investor questions can be addressed to .About NicoxNicox SA is an internat...

August 26, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox annonce la mise en ligne d’une page « Questions-Réponses » sur s...

Nicox annonce la mise en ligne d’une page « Questions-Réponses » sur son site internet Communiqué de presseNicox annonce la mise en ligne d’une page « Questions-Réponses » sur son site internet26 août 2025 – publication à 7H30Sophia Antipolis, FranceNicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui qu’une nouvelle page « Questions-Réponses » est disponible sur le site internet de la Société, , contenant des informations aux questions les plus fréquentes des actionnaires sur Nicox et son acti...

August 26, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial...

Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients Press Release Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients Achieving the primary endpoint in both Denali and the first NCX 470 Phase 3 trial, Mont Blanc, meets efficacy requirements for approval in the U.S. and ChinaNCX 470 was also superior to latanoprost in the reduction of intraocular pressure (IOP) from baseline (p

August 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch